Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab with and/or after first-line chemotherapy for previously untreated epithelial ovarian cancer
NL-OMON45949Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jul 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of avelumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 arms), sponsored by Pfizer. Primary endpoint: Progression-free survival. Started Jul 2017; status: active, not recruiting.
02
Drugs
avelumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NL-OMON45949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45949.